DE69400493T2 - Verwendung von Rifaximin und Rifaximin-enthaltende pharmazeutischen Zusammensetzungen zur Behandlung der durch Helicobacter Pylori verursachten Magendyspepsie - Google Patents

Verwendung von Rifaximin und Rifaximin-enthaltende pharmazeutischen Zusammensetzungen zur Behandlung der durch Helicobacter Pylori verursachten Magendyspepsie

Info

Publication number
DE69400493T2
DE69400493T2 DE69400493T DE69400493T DE69400493T2 DE 69400493 T2 DE69400493 T2 DE 69400493T2 DE 69400493 T DE69400493 T DE 69400493T DE 69400493 T DE69400493 T DE 69400493T DE 69400493 T2 DE69400493 T2 DE 69400493T2
Authority
DE
Germany
Prior art keywords
rifaximin
pharmaceutical compositions
helicobacter pylori
treatment
containing pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69400493T
Other languages
English (en)
Other versions
DE69400493D1 (de
Inventor
Antonella Ferrieri
Leone Gabriele Rotini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Wasserman SpA
Original Assignee
Alfa Wasserman SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wasserman SpA filed Critical Alfa Wasserman SpA
Application granted granted Critical
Publication of DE69400493D1 publication Critical patent/DE69400493D1/de
Publication of DE69400493T2 publication Critical patent/DE69400493T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69400493T 1993-03-23 1994-03-18 Verwendung von Rifaximin und Rifaximin-enthaltende pharmazeutischen Zusammensetzungen zur Behandlung der durch Helicobacter Pylori verursachten Magendyspepsie Expired - Lifetime DE69400493T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT93BO000099A IT1264494B1 (it) 1993-03-23 1993-03-23 Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter

Publications (2)

Publication Number Publication Date
DE69400493D1 DE69400493D1 (de) 1996-10-17
DE69400493T2 true DE69400493T2 (de) 1997-01-23

Family

ID=11338806

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69400493T Expired - Lifetime DE69400493T2 (de) 1993-03-23 1994-03-18 Verwendung von Rifaximin und Rifaximin-enthaltende pharmazeutischen Zusammensetzungen zur Behandlung der durch Helicobacter Pylori verursachten Magendyspepsie

Country Status (11)

Country Link
US (1) US5352679A (de)
EP (1) EP0616808B1 (de)
JP (1) JP2755550B2 (de)
KR (1) KR0177846B1 (de)
AT (1) ATE142495T1 (de)
CA (1) CA2115381C (de)
DE (1) DE69400493T2 (de)
DK (1) DK0616808T3 (de)
ES (1) ES2091649T3 (de)
GR (1) GR3020984T3 (de)
IT (1) IT1264494B1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US6902738B2 (en) * 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
WO1996024341A1 (en) * 1995-02-07 1996-08-15 Narayan Krishnarao Athanikar Concomitant treatment with bismuth and antibacterials
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5981522A (en) * 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
IT1290679B1 (it) * 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
TW534813B (en) * 1997-02-28 2003-06-01 Kaneka Corp Treating agent for diseases due to infection with helicobacter
AU2002360416A1 (en) * 2001-11-21 2003-06-10 Activbiotics, Inc. Targeted therapeutics and uses thereof
AU2002364162A1 (en) * 2001-12-13 2003-06-30 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
US7820652B2 (en) * 2003-09-24 2010-10-26 Activbiotics Pharma, Llc Regimen for the administration of rifamycin-class antibiotics
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
EP1698630B1 (de) 2005-03-03 2014-09-03 ALFA WASSERMANN S.p.A. Neue polymorphe Formen von Rifaximin, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
EP2837378A1 (de) † 2007-07-06 2015-02-18 Lupin Limited Pharmazeutische Zusammensetzungen aus Rifaximin
PT2327407E (pt) 2008-09-26 2014-09-10 Aska Pharm Co Ltd Agentes profiláticos e/ou terapêuticos para desordens gastrointestinais funcionais
PL3628319T3 (pl) 2008-10-02 2024-04-29 Salix Pharmaceuticals, Ltd. Leczenie encefalopatii wątrobowej za pomocą ryfaksyminy
US20110035232A1 (en) * 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2010044093A1 (en) * 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
RU2012126080A (ru) 2009-11-23 2013-12-27 Сипла Лимитед Местная пенообразующая композиция
JP2013511570A (ja) 2009-11-23 2013-04-04 シプラ・リミテッド 局所用泡沫組成物
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
US20130315988A1 (en) 2010-09-13 2013-11-28 Cipla Limited Pharmaceutical Composition
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
EP2927235B1 (de) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphe Mischung von Rifaximin und ihre Verwendung zur Herstellung fester Formulierungen
SI3546464T1 (sl) 2014-05-12 2020-09-30 Alfasigma S.P.A. Priprava in uporaba rifaksimina v kristalni obliki TAU solvatiranega z degme
CN106999477B (zh) * 2014-06-30 2020-04-10 萨利克斯药品公司 用于重复治疗肠易激综合征(ibs)的方法
CN110087688B (zh) 2016-10-14 2023-05-05 希普拉有限公司 包含利福昔明的药物组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica

Also Published As

Publication number Publication date
GR3020984T3 (en) 1996-12-31
DK0616808T3 (da) 1996-09-30
IT1264494B1 (it) 1996-09-24
ATE142495T1 (de) 1996-09-15
JPH06298768A (ja) 1994-10-25
JP2755550B2 (ja) 1998-05-20
US5352679A (en) 1994-10-04
ITBO930099A1 (it) 1994-09-23
ITBO930099A0 (it) 1993-03-23
KR0177846B1 (ko) 1999-03-20
CA2115381A1 (en) 1994-09-24
EP0616808A1 (de) 1994-09-28
EP0616808B1 (de) 1996-09-11
CA2115381C (en) 1999-01-05
ES2091649T3 (es) 1996-11-01
DE69400493D1 (de) 1996-10-17

Similar Documents

Publication Publication Date Title
DE69400493T2 (de) Verwendung von Rifaximin und Rifaximin-enthaltende pharmazeutischen Zusammensetzungen zur Behandlung der durch Helicobacter Pylori verursachten Magendyspepsie
UA32525C2 (uk) Стійка до шлункового соку форма лікарського засобу на основі пантопразолу для орального введення
HU9501206D0 (en) Pharmaceutical composition containing azithromycin
AU3728789A (en) Diphosphonic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
BG104727A (en) Pharmaceutical composition of topiramate
GEP20032925B (en) Benzothiepines Having Activity As Inhibitors of Ileal Bile Acid Transport and Taurocholate Uptake
IL136285A0 (en) Pharmaceutical compositions containing an acid-labile active component
DE69927584D1 (de) Pharmazeutische zubereitungen zur behandlung von magengeschwüren
EP1057828A3 (de) Trovafloxacin enhaltende Suspensionen zur oralen Anwendung
ATE215817T1 (de) Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis
WO1996022305A3 (en) Modified peptides
IL86077A0 (en) Receptor of the small rhinovirus receptor group,its preparation and pharmaceutical compositions containing it
IL85963A0 (en) Pharmaceutical compositions for the prophylaxis or treatment of disorders or diseases of the gastrointestinal tract,comprising antigenic substances
DE515995T1 (de) N-(5-thioxo-l-propyl)-l-cystein und derivate, deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen.
KR890004705A (ko) 항바이러스성 제제
CA2136801A1 (en) Pharmaceutical Agents for the Treatment of Disorders Caused by Helicobacter Pylori or Other Spiral Urease-Positive Gram-Negative Bacteria
DE58909594D1 (de) 6-Oxo-pyridazinderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
ATE85218T1 (de) Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid.
HK135494A (en) Azelastin embonate, process for its preparation and pharmaceutical compositions containing azelastin embonate as the active ingredient
DK0612763T3 (da) Cykliske angiopeptinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
IL99666A0 (en) Pharmaceutical compositions for the treatment of diabetes
RU2003133155A (ru) Способ эрадикации инфекции helicobacter pylori в желудке
EP0268868A3 (de) Pharmazeutische Zusammensetzungen zur Behandlung von gastrointestinalen Krankheiten
AU658197B2 (en) New use of benzimidazoline-2-oxo-1-carboxylic acid derivatives
UA43213A (uk) Спосіб лікування виразкової хвороби

Legal Events

Date Code Title Description
8364 No opposition during term of opposition